|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 235/14 | (2006.01) |
| A61P 35/02 | (2006.01) | ||
| A61K 31/4184 | (2006.01) |
| (11) | Number of the document | 3452035 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17793075.7 |
| Date of filing the European patent application | 2017-05-01 | |
| (97) | Date of publication of the European application | 2019-03-13 |
| (45) | Date of publication and mention of the grant of the patent | 2021-07-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/030414 |
| Date | 2017-05-01 |
| (87) | Number | WO 2017/192451 |
| Date | 2017-11-09 |
| (30) | Number | Date | Country code |
| 201662330673 P | 2016-05-02 | US |
| (72) |
DUNCAN, David , US
|
| (73) |
MEI Pharma, Inc. ,
11455 El Camino Real, Suite 250, San Diego, CA 92130,
US
|
| (54) | POLYMORPHIC FORMS OF 3-[2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL]-N-HYDROXY-ACRYLAMIDE AND USES THEREOF |
| POLYMORPHIC FORMS OF 3-[2-BUTYL-1-(2-DIETHYLAMINO-ETHYL)-1H-BENZOIMIDAZOL-5-YL]-N-HYDROXY-ACRYLAMIDE AND USES THEREOF |